Cao Y, Li PP, Qiao BL, Li QW. Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence. World J Gastrointest Oncol 2024; 16(7): 3118-3157 [PMID: 39072171 DOI: 10.4251/wjgo.v16.i7.3118]
Corresponding Author of This Article
Pei-Pei Li, MM, Attending Doctor, Department of Oncology, The Third People's Hospital of Zhengzhou, No. 136 Nanshuncheng Street, Guancheng District, Zhengzhou 450000, Henan Province, China. lpp20210224@126.com
Research Domain of This Article
Immunology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jul 15, 2024 (publication date) through Feb 15, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cao Y, Li PP, Qiao BL, Li QW. Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence. World J Gastrointest Oncol 2024; 16(7): 3118-3157 [PMID: 39072171 DOI: 10.4251/wjgo.v16.i7.3118]
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3118-3157 Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3118
Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence
Yang Cao, Pei-Pei Li, Bing-Li Qiao, Quan-Wang Li
Yang Cao, Pei-Pei Li, Bing-Li Qiao, Department of Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China
Quan-Wang Li, Department of Oncology, The Affiliated Oriental Hospital of Beijing University of Chinese Medicine, Beijing 100078, China
Author contributions: Cao Y conceived and designed research; Li PP performed experiments; Qiao BL interpreted results of experiments; Li QW analyzed data; Cao Y prepared figures; Li PP drafted paper; Qiao BL and Li QW edited and revised manuscript; All authors read and approved final version of manuscript.
Supported byHenan Province Medical Science and Technology Tackling Program Joint Co-Construction Project, No. LHGJ20191024.
Institutional review board statement: This study obtained approval from the Ethics Committee of The Third People's Hospital of Zhengzhou, and every patient signed an informed consent form following the Helsinki Declaration.
Institutional animal care and use committee statement: Animal research was performed following the Regulations on the Administration of Experimental Animals in Medical Research and the ARRIVE Guidelines for animal management and studies, and approval was obtained from the Institutional Animal Ethics Committee of The Third People's Hospital of Zhengzhou.
Informed consent statement: Every patient signed an informed consent form following the Helsinki Declaration.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request at lpp20210224@hhu.edu.cn.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Corresponding author: Pei-Pei Li, MM, Attending Doctor, Department of Oncology, The Third People's Hospital of Zhengzhou, No. 136 Nanshuncheng Street, Guancheng District, Zhengzhou 450000, Henan Province, China. lpp20210224@126.com
Received: September 27, 2023 Peer-review started: September 27, 2023 First decision: December 7, 2023 Revised: January 2, 2024 Accepted: March 20, 2024 Article in press: March 20, 2024 Published online: July 15, 2024 Processing time: 289 Days and 4.6 Hours
Core Tip
Core Tip: In this groundbreaking study, we explore the synergistic effects of Kombo Knife and sorafenib in hepatocellular carcinoma (HCC) treatment, utilizing insights from the cancer genome atlas. Employing advanced data analytics, including weighted gene coexpression network analysis and machine learning, we identify key immune genes-particularly peptidylprolyl isomerase A and solute carrier family 29 member 3-as significant prognostic markers. Our findings highlight the enhanced therapeutic efficacy of the combined regimen, marked by improved progression-free survival and response rates. This research represents a significant stride in HCC therapy, pivoting towards innovative, immune-centric treatment strategies that promise to transform patient outcomes.
